Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28207159 | 0.82 | KMT2A (0.37) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL9558795 | 0.80 | CA1 (0.37) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL9558792 | 0.80 | CA1 (0.37) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL3545332 | 0.80 | LTA4H (0.36) | DGAT1CA1CA2CA7NOS1 | |
| SCHEMBL3670262 | 0.77 | ADH1B (0.39) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL6799320 | 0.77 | NOS1 (0.35) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL5667907 | 0.77 | NOS1 (0.35) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL13686177 | 0.76 | MEN1 (0.33) | DGAT1CYP2D6CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL4825759 | 0.75 | NOS1 (0.34) | DGAT1CYP2D6CA1CA2CA7 | |
| SCHEMBL473139 | 0.74 | TSHR (0.36) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-1819711-B1 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | BAYER SCHERING PHARMA AG (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090186887-A1 | NOVEL PYRIMIDOTHIENOINDAZOLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-7511048-B2 | Pyrimidothienoindazoles | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | BAYER PHAMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1819711-A2 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | Bayer Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1799653-A2 | NOVEL HETEROCYCLES | Bayer Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006055268-A2 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006023843-A2 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | CCNI, TPMT, TYMP | DGAT1 3055/4885CYP2D6 309/4885CA1 4885/4885 |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | DGAT1 3345/4885CYP2D6 369/4885CA1 4885/4885 |
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | DGAT1 4213/4885CYP2D6 518/4885CA1 4830/4885 |
| US-20090186887-A1 | NOVEL PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | DGAT1 3055/4885CYP2D6 309/4885CA1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.